NCT07730567Not yet recruitingPhase 1
A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-236A and AD-236B
A Two-arm, Open-label, Single-sequence, Multiple-dose Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-236A and AD-236B in Healthy Adult Volunteers
Source: ClinicalTrials.gov · Last updated 28 Jul 2026
Brief summary (registry, in English)
To evaluate the pharmacokinetic interaction and the safety of AD-236A and AD-236B in healthy adult volunteers
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 44 (estimated)
- First submitted
- 23 Jul 2026
- Start date
- 29 Jul 2026
- Primary completion date
- 13 Sept 2026
- Lead sponsor
- Addpharma Inc.
- Diseases
- Type 2 diabetes
- NCT number
- NCT07730567
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 44
- From 29 Jul 2026 to the primary completion date, 13 Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration
Other
- Other exclusions applied
Who the study is looking for
- Healthy adult volunteers aged ≥19 and ≤55 years at the time of the screening visit
- Body weight ≥50 kg (≥45 kg for females) and body mass index (BMI) between 18.0 kg/m² and 30.0 kg/m² at the time of the screening visit
Age in the registry: 19 years to 55 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| H+ Yangji Hospital, Seoul, Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.